

Design and synthesis of novel tetrahydronaphthyl azoles and related Cyclohexyl azoles as antileishmanial agents

Vijay K. Marrapu,^a Nagarapu Srinivas,^a Monika Mittal,^b Nishi Shakya,^b Suman
Gupta^b and Kalpana Bhandari,^{a,*}

^aMedicinal and Process Chemistry Division, Central Drug Research Institute, CSIR, Lucknow 226001, ^bDivision of Parasitology, Central Drug Research Institute, CSIR, Lucknow 226001, India.

*Corresponding author. Tel.: +91 522 2262411x 4379; fax: +91 522 2623405;
e-mail addresses: bhandarikalpana@rediffmail.com; kalpana_bhandari@cdri.res.in.

Abstract: A novel series of *trans*-2-aryloxy-1,2,3,4-tetrahydronaphthyl azoles and related cyclohexyl azoles were synthesized and evaluated *in vitro* against *Leishmania donovani*. Compound **9** identified as most active analog with IC₅₀ value of 0.64 µg/mL and SI value of 34.78 against amastigotes, and is several folds more potent than the reference drugs sodium stilboglucuronate and paromomycin. It also exhibited significant *in vivo* inhibition of 83.33%, and provided a new structural scaffold for antileishmanials.

Keywords: Antileishmanial; azoles; aryloxy tetrahydronaphthalene

Introduction

There is a lack of effective, safe, and affordable pharmaceuticals to control neglected tropical diseases (NTDs) such as leishmaniasis that cause high mortality and morbidity among poor people in the developing world. The NTDs are a group of chronic and debilitating conditions, caused by parasitic, bacterial, and other infections.¹

Leishmaniasis, a parasitic disease caused by organisms of the *Leishmania* genus, comprises three clinical forms: visceral, cutaneous, and mucocutaneous.² The lesions may be confined to skin, in the case of cutaneous leishmaniasis, or may invade subcutaneous tissue, as in the potentially fatal visceral form, depending on the infecting organism and the immunological status of the host.³ Chemotherapeutic treatment of leishmaniasis usually relies on the use of pentavalent antimonials such as sodium stibogluconate (Pentostam) and meglumine antimoniate (Glucantime), but toxic side effects and drug resistance are frequently encountered.⁴ The second-line compounds used during the treatment of unresponsive cases generally include pentamidine and amphotericin B and its lipid formulations.⁵ The oral anticancer drug miltefosine⁶ is an effective drug, but there are side effects and drawbacks related to treatment. Antifungal imidazole and triazole derivatives such as ketoconazole, fluconazole and itraconazole, which block ergosterol biosynthesis at the level of cytochrome P-450-dependent C14-demethylase,⁷ are also effective against different *Leishmania* species both *in vitro* and *in vivo*. Various *N*-substituted azole derivatives have also been reported with promising *in vitro* antileishmanial activity.⁸ *Leishmania* resemble fungi in synthesizing 24-substituted sterols such as ergosterol, while mammals have just cholesterol, it accounts for many antifungal sterol biosynthesis inhibitors (SBIs) to also be leishmanicidal. Ketoconazole and fluconazole have undergone evaluation in VL in India.⁹ However, despite reports of their usefulness, the antileishmanial activity was not enough to induce clinical cure by themselves. Thus, the development of new, efficient, and safe drugs for the treatment of this disease is imperative.

Recently, we reported on the synthesis of a series of novel aryloxy alkyl and aryloxy aryl alkyl imidazoles¹⁰ as potential antileishmanial agents. Based on the above report and in continuation of our efforts to generate azole based novel antileishmanial agents,¹¹ we synthesized a series of novel aryloxy tetrahydronaphthyl azoles (**4-13**) and related cyclohexyl azoles (**22-28**) (Figure 1) and evaluated them *in vitro* against the *Leishmania* parasites. Many of these derivatives were found to possess strong inhibitory activity against *L. donovani* when compared to the standard drug. After this large *in vitro* screening, compound **9** and **10**, identified as the most active analogs of the series, were selected for *in vivo* analysis and the results are reported in this communication.






Figure 1. Aryloxy tetrahydronaphthyl and cyclohexyl azoles

The synthesis of compounds **4-13** was carried out according to scheme 1. The regioselective ring opening of 1,2-epoxy-tetrahydronaphthalene¹² **1** with imidazole in absolute ethanol furnished *trans*-1-imidazol-1-yl-1,2,3,4-tetrahydro-naphthalen-2-ol (**3a**). The **3a** can also be prepared directly from the bromohydrin¹¹ **2** in low yields (27–28 %). The 1,2,3-triazole did not react with epoxide **1** under similar conditions. However, the reaction was achieved under solvent free, PTC catalyzed condition to give the product 1-[1,2,3]-triazol-1-yl-1,2,3,4-tetrahydro-naphthalen-2-ol (**3b**) in excellent yields (~ 83 %). Further, etherification of the hydroxyl intermediates **3a** & **3b** with substituted aryl (benzyl and benzo) halides furnished the desired ethers **4-13** (Scheme 1). The ¹HNMR spectra of compounds **4-13** showed a doublet at approximately δ 5.3 for H-1 proton with $J_{1-2} = 7-8$ Hz, indicative of a *trans* diaxial orientation. The benzyloxy compounds **9**, **10** and **13** gave the splitting pattern of its diastereotopic benzylic protons H_a and H_b as an AB quartet type signal multiplicity at δ 4.3–4.6 ppm with coupling constant $J_{AB} = 13.1$ Hz.




Scheme 1. Reagents and conditions: (i) Imidazole / abs. ethanol. (ii) 1,2,3-triazole / (But)₄N⁺ I⁻. (iii) Imidazole / acetonitrile. (iv) NaH (60 % Oil), substituted aryl or halo benzene / DMF.

It was thought interesting to synthesize and evaluate the above ethers with *cis* geometry (scheme 2). Benzoylation of the *trans*-1-amino-2-hydroxytetrahydronaphthalene^{13a} (**14**) followed by treatment with thionyl chloride gave the 2-phenyl oxazoline (**15**) which was hydrolyzed with 6N H₂SO₄ to furnish the required *cis* amino alcohol^{13b} **16**. Reaction of the *cis* amino alcohol **16** with ammonium acetate, glyoxal and paraformaldehyde in methanol under refluxing condition gave the desired *cis*-1-imidazol-1-yl-1,2,3,4-tetrahydro-naphthalen-2-ol (**17**). However, the etherification of *cis*-imidazolyl alcohol **17** with aryl halides did not give the desired *cis* ethers (**18**) but furnished the dehydrated product **19**.



Scheme 2. Reagents and conditions: (i) PhCOCl, KOH, H₂O, rt, 3h; (ii) SOCl₂, CH₂Cl₂, rt, 7h; (iii) 6N.H₂SO₄, reflux, 11h; (iv) glyoxal, NH₄OAc, HCHO, methanol, 80°C, 8h; (v) NaH (60% Oil), substituted aryl or benzyl halide, DMF, 0°C-rt, 4-5h.

Further, for SAR studies the related aryloxy cyclohexyl imidazoles (**22-28**) were also prepared (scheme 3). Reaction of imidazole with 1,2-epoxycyclohexane (**20**) under refluxing conditions furnished *trans*-2-imidazolyl cyclohexanol (**21**). Etherification of the hydroxyl intermediate with substituted aryl halides furnished the corresponding ethers **22-28**. All the compounds shown in schemes 1-3 were obtained as racemic mixtures.



Scheme 3. Reagents and conditions: (i) Imidazole, abs. ethanol, 90°C, 12h; (ii) NaH (60% Oil), substituted aryl or benzyl halide, DMF, 0°C-rt, 4-5h.

The compounds selected for study (**4–13**, & **22–28**) were evaluated *in vitro* against transgenic *L. donovani* promastigotes and intracellular amastigotes¹⁴ at various concentrations and cytotoxicity responses¹⁴ were assessed using mouse macrophage cell line (J-774-A-1) and taking sodium stibogluconate and pdophyllotoxin (for cytotoxicity assay) as controls. Cell viability was determined using the MTT assay.¹⁵ CC_{50} values were estimated through the preformed template as described by Huber and Koella.¹⁶ IC_{50} of antileishmanial activity was calculated by nonlinear regression analysis of the concentration – response curve using the four parameter Hill equations. Any synthesized analogues with *in vitro* IC_{50} value exceeding above 15 $\mu\text{g} / \text{mL}$ was considered as inactive. Based on IC_{50} and SI values two compounds were further evaluated for *in vivo* activity intraperitoneally at 50mg / kg \times 10 i.p dose against *L. donovani* / Hamster model (*Mesocricetus auretus*).¹⁷

The *in vitro* biological activities of aryloxy tetrahydronaphthyl azoles / aryloxy cycloalkyl azoles (**4–13**, **22–28**) have shown encouraging results against *L. donovani*. Table 1 displays % inhibition (promastigotes), IC_{50} and SI values of the synthesized azoles against intracellular amastigotes. Interestingly, all the compounds (except **4**) exhibited high inhibition of 89–100% at 10 $\mu\text{g}/\text{mL}$ concentration against promastigotes. These compounds were further evaluated against amastigotes and IC_{50} and SI values were calculated. Two compounds **9** and **13** of SI above 10 were tested further for *in vivo* leishmanicidal activity and the results are presented in Table 1.

The IC_{50} values for amastigotes of the test derivatives indicate that 13 compounds out of 17 exhibited high activity against *L. donovani* (IC_{50} 0.64–6.52 $\mu\text{g}/\text{mL}$), better than the reference drugs sodium stibogluconate (IC_{50} = 46.54 $\mu\text{g}/\text{mL}$). The hydroxyl intermediates (**3a** & **3b**), showed either low inhibition or no inhibition. Further, conversion of hydroxyl group to aryloxy/ benzyloxy moiety (compounds **5–13** & **22–28**, Table 1) resulted in enhancing the activity several folds (IC_{50} 0.64–6.52 $\mu\text{g}/\text{mL}$).

Among the tetrahydronaphthyl azole series (**5–13**) the compounds with benzyloxy moiety (**9**, **10** & **13**) appeared more active compare to the aryloxy analogs exerting a strong inhibitory effect on the amastigote form of parasite, while three compounds (**9**, **10** and **13**) produced an interesting selective anti-amastigote activity (SI > 10). The aryloxy triazole derivatives **11** & **12** were found inactive whereas the benzyloxy triazole derivative **13** expressed good anti-amastigote activity (IC_{50} =3.01 $\mu\text{g}/\text{mL}$) with SI = 10.01, was slightly less active than its imidazole counterpart **10** (IC_{50} =1.34 $\mu\text{g}/\text{mL}$ and SI = 11.53).

Further, to investigate the SAR effect of phenyl ring, we also synthesized and evaluated a set of aryloxy cyclohexyl azoles (**22–28**). Though, these compounds displayed a strong inhibitory activity on the intracellular amastigote IC_{50} ranging from 1.40 to 5.07 $\mu\text{g}/\text{mL}$, but the selective index of all the compounds was below 10, revealing the presence of the phenyl rings is crucial for better activity profile.

The overall activity profile of compounds (**4–13**, **22–28**) demonstrated that there is a small difference in their IC_{50} values. Thus, the biological activity was slightly influenced by the type of substituent attachment at the 2 and 4-position of the aryloxy nucleus (except in compounds **4** and **22** where the CF_3 group at 4-position renders the molecule inactive). However, it is interesting to note that the introduction of NO_2 group at position 2 together with 4- CF_3 imparted increased selectivity (**8** & **25**). Similarly, the NO_2 group at position 4 (**5** & **23**) renders the molecule moderately active, while the presence of a fluorine atom at 2 position together with 4- NO_2 enhances the activity (**7** and **24**). Moreover, the presence of a CF_3 group at 2 position together with 4- NO_2 further confers increased selectivity (**6**). Among the benzyloxy analogues the 2,5-dichloro derivative **9** and 3-chloro- derivatives **10**, **13** & **26** displayed the highest selectivity index (34.78, 11.53, 10.03 and 9.10 respectively).

Two compounds (**9** and **10**) of SI above 10 were tested further for in vivo leishmanicidal activity. Compound **9** the 2,5-dichlorobenzoyloxy tetrahydronaphthyl imidazole, exhibited significant in vivo activity with 83.33% inhibition of parasite growth while compound **10** (3-chlorobenzoyloxy tetrahydronaphthyl triazole) displayed moderate activity with 32.10% inhibition. It is interesting to note that in both the series (**4–13**, and **22–28**) the highest activity (SI values) was shown by the compounds with either a 2,5-dichloro or a 3-chloro benzyloxy moiety. This finding indicates that benzyloxy moiety with chloro substituents should be investigated for the development of highly selective antileishmanial compounds.

Table 1: *In vitro* and *in vivo* antileishmanial activity of synthesized azoles

Sl.No.	Compd. No.	<i>In Vitro</i> Assessment		^a Cytotoxicity CC ₅₀ (μg/mL)	Selective index *(SI) CC ₅₀ /IC ₅₀	<i>In vivo</i> activity (Dose- 50mg/kg × 10 i.p.) Percent inhibition
		Anti Promastigote activity (% inhibition at 10μg/mL)	Anti amastigote activity. #IC ₅₀ (μg/mL) (C.I)			
1	3a	60	>50	>100,	2	
2	3b	90.42	NI	35.59	NA	
3	4	60	NI	52.46	NA	
4	5	94.89	4.53	21.43	4.73	
5	6	91.16	1.59	10.69	6.73	
6	7	100	6.52	32.13	4.92	
7	8	99.59	3.58	20.08	5.61	
8	9	100	0.64	22.26,	34.78	83.33 ± 6.16
9	10	100	1.34	15.46	11.53	32.10 ± 8.51
10	11	99.62	NI	>100	NA	
11	12	100	NI	>100	NA	
12	13	100	3.01	30.20	10.03	
13	22	99.80	NI	ND	NA	
14	23	98.56	2.23	8.27	3.70	
15	24	95.69	2.15	14.25	6.62	
16	25	99.00	5.07	22.13	4.36	

17	26	96.91	1.404	12.76	9.10	
18	27	89.57	4.03	27.16	6.73	
19	28	99.47	2.44	3.43	1.41	
20	SSG	946.52	46.54	297.38	6.38	92.20 ± 5.25
21	Paromomycin	123.92	24.79	53.33	2.15	46.7 ± 9.82

IC₅₀ > 15 µg/mL = Inactive; IC₅₀ > 5-15 µg/mL = Moderately active; IC₅₀ < 5 µg/mL = Highly active compounds; ^aCC₅₀ (cytotoxic concentration for 50 % inhibition) is evaluated against J-774A-1 cell lines; NI = no inhibition at 10 µg/mL; ND = not done; NA = not available; SSG = sodium stibogluconate.

These results clearly indicate that newly synthesized tetrahydronaphthyl azoles reported herein are promising compounds and provide useful model for further structural and biological optimization. Compound **9** displayed not only a lower (38 to 72 times) IC₅₀ value than that of the reference drugs, but also 6- & 16-fold more selective (S.I. = 34.78) as compared to that of standard drugs sodium stibogluconate and paromomycin, respectively. The study opens up the possibility of advancing this new class of compounds as novel antileishmanial agents. Further studies on these compounds to optimize the efficacy is in progress in our laboratory.

Acknowledgments

V.K.M. is grateful to Council of Scientific and Industrial Research (India) for the award of Junior Research Fellowship. The authors are thankful to Anoop K. Srivastava for providing technical assistance. All are thankful to SAIF for spectroscopic analysis of the compounds.

CDRI communication No: .

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:

References

- Hotez, P. J.; Molyneux, D. H.; Fenwick, A.; Kumaresan, J.; Sachs, S. E.; Sachs, J. D.; Savioli, L. N. *Eng. J. Med.* **2007**, *357*, 1018.
- Sharma, U.; Singh, S. J. *Vector Borne Dis.* **2008**, *45*, 255.
- Solbach, W.; Laskay, T. *Adv. Immunol.* **1999**, *74*, 275.
- (a) Herwaldt, B. L.; Berman, J. D. *Am. J. Trop. Med. Hyg.* **1992**, *46*, 296. (b) Esfandiarpour, I.; Alavi, A. *Int. J. Dermatol.* **2002**, *41*, 521.
- Wortmann, G.; Zapor, M.; Ressler, R.; Fraser, R.; Hartzell, J.; Pierson, J.; Weintrob, A.; Magill, A. *Am. J. Trop. Med. Hyg.* **2010**, *83*, 1028.
- Sundar, S.; Jha, T. K.; Thakur, C. P.; Engel, J.; Sindermann, H.; Fisher, C.; Junge, K.; Bryceson, A.; Berman, J. N. *Eng. J. Med.* **2002**, *347*, 1739.

7. (a) Martínez, M. D. N.; Herrera, J. C.; López, J. N. R. *Int. J. Antimicrob. Agents* **2006**, *28*, 560. (b) Urbina, J. A. *Parasitology* **1997**, *114*, S91. (c) Al-Abdely, H. M.; Graybill, J. R.; Loebenberg, D.; Melby, P. C. *Antimicrob. Agents Chemother.* **1999**, *43*, 2910.
8. (a) Ferreira, S. B.; Costa, M. S.; Boechat, N.; Bezerra, R. J. S.; Genestra, M. S.; Canto-Cavalheiro, M. M.; Kover, W. B.; Ferreira, V. F. *Eur. J. Med. Chem.* **2007**, *42*, 1388. (b). Foroumadi, A.; Emami, S.; Pournourmohammadi, S.; Kharazmi, A.; Shafiee, A. *Eur. J. Med. Chem.* **2005**, *40*, 1346.
9. Alrajhi, A. A.; Ibrahim, E. A.; De Vol, E. B.; Khairat, M.; Faris, R. M.; Maguire, J. H. *N. Eng. J. Med.* **2002**, *346*, 891.
10. Bhandari, K; Srinivas, N.; Marrapu, V. K.; Verma, A.; Srivastava, S.; Gupta, S. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 291.
11. (a) Srinivas, N.; Palne, S.; Nishi.; Gupta, S.; Bhandari, K. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 324. (b) Bhandari, K.; Srinivas, N.; Palne, S.; Nishi; Gupta, S. *Ind. Pat.* 610 DEL **2008**.
12. Bhandari, K.; Sharma, V. L.; Singh, C. M.; Shanker, G.; Singh, H. K. *Ind. J. Chem.* **2000**, *39B*, 468.
13. (a) Bhandari, K.; Srivastava, S.; Shanker, G. *Bioorg & Med. Chem.* **2004**, *12*, 418. (b) Matsuoka, Y.; Ishida, Y.; Sasaki, D.; Saigo, K. *Tetrahedron.* **2006**, *62*, 8199.
14. Ashutosh; Gupta, S.; Ramesh; Sundar, S.; Goyal, N. *Antimicrob. Agents Chemother.* **2005**, *49*, 3776.
15. Mossman, T. J. *J. Immunol. Methods* **1983**, *65*, 55.
16. Huber, W.; Koella, J. C. *Acta Tropica.* **1993**, *55*, 257.
17. Gupta, S.; Tiwari, S.; Bhaduri, A. P.; Jain, G. K. *Acta Tropica.* **2002**, *84*, 165.